7 research outputs found

    Immunoglobulin G subclass switching impacts sensitivity of an immunoassay targeting <i>Francisella tularensis</i> lipopolysaccharide

    No full text
    <div><p>The CDC Tier 1 select agent <i>Francisella tularensis</i> is a small, Gram-negative bacterium and the causative agent of tularemia, a potentially life-threatening infection endemic in the United States, Europe and Asia. Currently, there is no licensed vaccine or rapid point-of-care diagnostic test for tularemia. The purpose of this research was to develop monoclonal antibodies (mAbs) specific to the <i>F</i>. <i>tularensis</i> surface-expressed lipopolysaccharide (LPS) for a potential use in a rapid diagnostic test. Our initial antigen capture ELISA was developed using murine IgG3 mAb 1A4. Due to the low sensitivity of the initial assay, IgG subclass switching, which is known to have an effect on the functional affinity of a mAb, was exploited for the purpose of enhancing assay sensitivity. The ELISA developed using the IgG1 or IgG2b mAbs from the subclass-switch family of 1A4 IgG3 yielded improved assay sensitivity. However, surface plasmon resonance (SPR) demonstrated that the functional affinity was decreased as a result of subclass switching. Further investigation using direct ELISA revealed the potential self-association of 1A4 IgG3, which could explain the higher functional affinity and higher assay background seen with this mAb. Additionally, the higher assay background was found to negatively affect assay sensitivity. Thus, enhancement of the assay sensitivity by subclass switching is likely due to the decrease in assay background, simply by avoiding the self-association of IgG3.</p></div

    LPS binding affinity of each 1A4 subclass mAb analyzed by SPR using an antibody capture analysis approach.

    No full text
    <p>Anti-mouse antibody was covalently immobilized on a CM5 sensor chip. Each subclass of mAb 1A4 was injected individually over the chip surface, followed by injection of various concentrations of LPS (60–8,000 nM). Data shown is representative of three independent experiments with similar results. <b>Panel A</b> illustrates the complex formed on the chip surface. <b>Panel B</b> presents the sensorgrams (<b>top</b>) and steady-state binding analysis (<b>bottom</b>) of each 1A4 subclass variant.</p

    SPR analysis of LPS binding of mAbs 1A4 IgG3, IgG1 and IgG2b using a biotinylated LPS-streptavidin capture platform.

    No full text
    <p>Biotinylated LPS was immobilized on a streptavidin (SA) sensor chip. Sensorgrams were generated by injecting different concentrations of mAbs 1A4 IgG3 (10.4–333 nM), 1A4 IgG1(1.7–8 μM) or 1A4 IgG2b (0.1–3.3 μM) over the chip surface. Data shown is representative of three independent experiments with similar results. <b>Panel A,</b> a diagram depicting the antigen-antibody complex (and a proposed antibody-antibody interaction) formed on the chip surface. <b>Panel B</b> presents the sensorgram profile of 1A4 IgG3 (<b>left</b>) and the corresponding steady-state affinity determination (<b>right</b>). The sensorgrams for 1A4 IgG1 and IgG2b are presented in <b>Panels C and D</b>, respectively.</p

    Antibody-antibody interaction as determined by direct ELISA.

    No full text
    <p><b>Panel A</b>, the binding interactions between 1A4 IgG3 and each mAb subclass are demonstrated. <b>Panel B</b>, self-association of each subclass of the mAb 1A4 are shown. The experiments were carried out in quadruplicate. Data shown are mean ± standard deviation.</p

    Specificity of mAbs 1A4 and FB11.

    No full text
    <p>Inactivated <i>F</i>. <i>tularensis</i> SCHU S4 (lane 1), SCHU S4 ΔwbtI (lacks <i>O</i>-antigen, lane 2), LVS (lane 3), <i>F</i>. <i>tularensis</i> subsp. <i>holarctica</i> (lane 4), subsp. <i>novicida</i> (lane 5), <i>F</i>. <i>philomiragia</i> (lane 6), purified <i>B</i>. <i>pseudomallei</i> LPS (lane 7) and <i>E</i>. <i>coli</i> LPS (lane 8) were separated on 12% SDS-PAGE gels and blotted onto nitrocellulose membranes. The membranes then were probed with mAbs 1A4 IgG3 (<b>Panel A</b>) and FB11 (<b>Panel B</b>). The existence of LPS in these samples was demonstrated by Pro-Q emerald 300 LPS staining (<b>Panel C</b>).</p

    Competition ELISA for LPS binding of 1A4 subclass variants.

    No full text
    <p>Each 1A4 subclass mAb was assessed for its ability to compete with 1A4 IgG1 HRP conjugate for binding to LPS. Dose-response curve (%inhibition <i>vs</i> mAb concentration) of each 1A4 subclass variant was created by mixing HRP-labeled 1A4 IgG1 (fixed concentration) with various concentrations of unlabeled mAb (1A4 IgG3, IgG1 or IgG2b) before adding to microtiter plates pre-coated with LPS. Percent inhibition was calculated by % inhibition = [(OD<sub>450</sub> of 1A4 IgG1 HRP alone–OD<sub>450</sub> of 1A4 IgG1 HRP plus unlabeled mAb)/ OD<sub>450</sub> of 1A4 IgG1 HRP alone] x 100. The analysis was performed in quadruplicate and data shown are mean ± standard deviation. The IC<sub>50</sub> values were calculated from the sigmoidal dose-response curve model using SigmaPlot software.</p
    corecore